Invivyd, Inc. (NASDAQ:IVVD) Director Sells $94,636.00 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00. Following the completion of the transaction, the director now owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This trade represents a 3.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Trading Down 5.7 %

Shares of IVVD opened at $0.55 on Friday. Invivyd, Inc. has a 12 month low of $0.54 and a 12 month high of $5.20. The firm has a fifty day simple moving average of $0.83 and a 200 day simple moving average of $1.07. The stock has a market capitalization of $65.43 million, a price-to-earnings ratio of -0.28 and a beta of 0.53.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IVVD. Vanguard Group Inc. boosted its holdings in Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after purchasing an additional 97,496 shares during the last quarter. SG Americas Securities LLC raised its position in Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after acquiring an additional 25,201 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Invivyd during the second quarter worth $263,000. Rhumbline Advisers raised its position in Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after acquiring an additional 82,164 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after acquiring an additional 474,301 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IVVD shares. HC Wainwright reduced their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Morgan Stanley reduced their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Invivyd presently has a consensus rating of “Buy” and a consensus price target of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.